文献速递泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

儿童肾肿瘤的生物学与治疗

Biology and treatment of renal tumours in childhood.
PubMed 文献 · Eur J Cancer · 2016-10-28

欧洲每年近1000名儿童诊断为恶性肾肿瘤,绝大多数为肾母细胞瘤(Wilms瘤),按SIOP-RTSG方案术前化疗、手术及术后分层治疗,总生存率接近90%,但高危组织学或复发亚组及罕见非Wilms瘤预后差;本文综述儿童肾肿瘤生物学进展并介绍即将开展的SIOP-RTSG UMBRELLA研究。

要点

  • 肾母细胞瘤总生存率接近90%,高危组织学或复发亚组预后仍差。
  • 非Wilms瘤如恶性横纹肌样瘤、转移性透明细胞肉瘤及转移性肾细胞癌预后差。
  • 多数横纹肌样瘤存在SMARCB1基因突变,CCSK与儿童RCC遗传基础更异质。

核心结论

  • 改善高危亚组预后需通过生物学洞察进行更准确的风险分层,并需生物标志物指导靶向治疗。
  • 持续国际合作以标准化诊断治疗并整合生物标志物研究,构成即将开展的SIOP-RTSG UMBRELLA研究的依据。

研究设计与样本

  • 综述,概述儿童肾肿瘤当前生物学知识及国际合作进展,并介绍即将开展的SIOP-RTSG UMBRELLA研究。

主要发现

  • 欧洲每年近1000名儿童诊断为恶性肾肿瘤,绝大多数为肾母细胞瘤。
  • 肾母细胞瘤总生存率接近90%,但高危组织学或复发亚组预后仍差。
  • 罕见非Wilms瘤预后同样差,尤其恶性横纹肌样瘤、转移性透明细胞肉瘤及转移性肾细胞癌。
  • 多数横纹肌样瘤显示SMARCB1基因体细胞和/或胚系突变,CCSK与儿童RCC遗传基础更异质,包括特征性易位。
  • 靶向治疗早期试验因难治复发患者稀少、复发进展快及肿瘤遗传异质性而具挑战。

临床怎么用

  • 多数儿童按SIOP-RTSG方案接受术前化疗、手术及依据分期和组织学的术后治疗。
  • 原文未据此给出推荐。

局限性

  • 靶向治疗早期试验因难治或复发患者稀少、复发进展快及肿瘤遗传异质性(个体体细胞突变患病率低)而具挑战。
  • 改善人群生存率还需考虑欧洲各地结局的地理差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In Europe, almost 1000 children are diagnosed with a malignant renal tumour each year. The vast majority of cases are nephroblastoma, also known as Wilms' tumour (WT). Most children are treated according to Société Internationale d'Oncologie Pédiatrique Renal Tumour Study Group (SIOP-RTSG) protocols with pre-operative chemotherapy, surgery, and post-operative treatment dependent on stage and histology. Overall survival approaches 90%, but a subgroup of WT, with high-risk histology and/or relapsed disease, still have a much poorer prognosis. Outcome is similarly poor for the rare non-WT, particularly for malignant rhabdoid tumour of the kidney, metastatic clear cell sarcoma of the kidney (CCSK), and metastatic renal cell carcinoma (RCC). Improving outcome and long-term quality of life requires more accurate risk stratification through biological insights. Biomarkers are also needed to signpost potential targeted therapies for high-risk subgroups. Our understanding of Wilms' tumourigenesis is evolving and several signalling pathways, microRNA processing and epigenetics are now known to play pivotal roles. Most rhabdoid tumours display somatic and/or germline mutations in the SMARCB1 gene, whereas CCSK and paediatric RCC reveal a more varied genetic basis, including characteristic translocations. Conducting early-phase trials of targeted therapies is challenging due to the scarcity of patients with refractory or relapsed disease, the rapid progression of relapse and the genetic heterogeneity of the tumours with a low prevalence of individual somatic mutations. A further consideration in improving population survival rates is the geographical variation in outcomes across Europe. This review provides a comprehensive overview of the current biological knowledge of childhood renal tumours alongside the progress achieved through international collaboration. Ongoing collaboration is needed to ensure consistency of outcomes through standardised diagnostics and treatment and incorporation of biomarker research. Together, these objectives constitute the rationale for the forthcoming SIOP-RTSG 'UMBRELLA' study.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Brok J, Treger TD, Gooskens SL, et al. Biology and treatment of renal tumours in childhood. Eur J Cancer. 2016. PMID: 27969569. doi:10.1016/j.ejca.2016.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。